Introduction {#s1}
============

Endothelial cells line the lumen of all blood vessels and regulate multiple functions, including contractility. A wide variety of different stimuli act through endothelial cells to control arterial contractility, including receptor ligands, such as acetylcholine (ACh), and mechanical force, including intravascular flow. Mechanisms by which endothelial cells regulate arterial contractility include the production of diffusible substances, such as nitric oxide (NO) and hydrogen sulfide, and the release of endothelium-derived hyperpolarizing factors, including potassium (K^+^) ([@bib56]; [@bib14]; [@bib28]). Due to the presence of myoendothelial gap junctions, endothelial cells can also directly control smooth muscle cell membrane potential to regulate arterial contractility ([@bib22]). Less well defined are signaling mechanisms by which physiological stimuli activate these processes in endothelial cells to produce vasodilation. In particular, the regulatory mechanisms, physiological functions and in vivo significance of many ion channels that are expressed in endothelial cells are poorly understood.

Endothelial cells express several different families of ion channels, including multiple transient receptor potential (TRP), small-conductance Ca^2+^-activated K^+^ (SK3, K~Ca~2.3) and intermediate-conductance Ca^2+^-activated K^+^ (IK, K~Ca~3.1) proteins ([@bib25]). TRP channels are a family of \~28 proteins that are subdivided into six different classes, including polycystin (TRPP), melastatin (TRPM), ankyrin (TRPA), canonical (TRPC) and vanilloid (TRPV) ([@bib13]). Studies performed using whole arteries and veins, which contain multiple different cell types, and cultured and non-cultured cells have proposed that approximately twenty different TRP channels may be expressed in endothelial cells ([@bib50]; [@bib4]). A significant body of work indicates that TRPV4 channels present in endothelial cells regulate the contractility of vasculature, including resistance-size arteries ([@bib11]; [@bib47]; [@bib64]; [@bib26]; [@bib32]). Evidence also suggests that endothelial cell TRPA1, TRPC3, TRPC4, TRPV1 and TRPV3 channels modulate vascular contractility ([@bib30]; [@bib20]; [@bib18]; [@bib62]; [@bib2]; [@bib12]; [@bib49]). In many of these previous studies, TRP channel expression and or function was reported in endothelial cells of ex vivo vasculature that does not control systemic blood pressure, including conduit vessels, cerebral arteries, mammary arteries and umbilical vein ([@bib13]; [@bib20]). Physiological functions of many TRP channels that are proposed to be expressed in endothelial cells are poorly understood, particularly in small resistance-size arteries that regulate regional organ blood flow and systemic blood pressure.

PKD2, which is also termed Transient Receptor Potential Polycystin 1 (TRPP1), PC-2 and polycystin-2, is encoded by the *Pkd2* gene ([@bib38]). PKD2 contains six transmembrane domains, cytoplasmic N and C termini and a characteristic extracellular polycystin domain ([@bib46]). PKD2 protein is expressed in a wide variety of different cell types, including endothelium, arterial smooth muscle, renal epithelia, cardiac myocytes and neurons, ([@bib4]; [@bib45]). Mutations in *Pkd2* lead to Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most prevalent monogenic human disease worldwide ([@bib52]). ADPKD is typically characterized by the growth of renal cysts, although a significant proportion of patients develop hypertension prior to kidney dysfunction, suggesting PKD2 channels perform physiological functions in vascular wall cell types ([@bib52]; [@bib55]; [@bib33]). We have previously shown that intravascular pressure and α~1~-adrenoceptors activate PKD2 channels in arterial smooth muscle cells of different organs, leading to depolarization, vasoconstriction and an increase in systemic blood pressure ([@bib4]). In contrast, regulatory mechanisms and physiological functions of PKD2 channels in endothelial cells are unclear.

Here, we developed an inducible, cell-specific, knockout mouse model to study physiological functions of PKD2 channels in endothelial cells. We show that intravascular flow stimulates PKD2 channels in endothelial cells and that this mechanism is a major contributor to flow-mediated vasodilation over a broad shear stress range. In contrast, PKD2 channels do not contribute to ACh-induced dilation, suggesting stimulus-specific function. Flow-mediated PKD2 channel activation leads to Ca^2+^ influx, which activates SK and IK channels, and stimulates eNOS. These mechanisms induce arterial hyperpolarization, vasodilation and a reduction in blood pressure. Thus, PKD2 channels are a major contributor to functional flow-sensing in endothelial cells.

Results {#s2}
=======

Generation of tamoxifen-inducible, endothelial cell-specific PKD2 knockout mice {#s2-1}
-------------------------------------------------------------------------------

Mice with *loxP* sites flanking exons 11 and 13 (*Pkd2^fl/fl^*) of the *Pkd2* gene were crossed with tamoxifen-inducible, endothelial cell-specific Cre (*Cdh5*-creERT2) mice, producing a *Pkd2^fl/fl^:Cdh5*-creERT2 line. Genomic PCR confirmed that tamoxifen stimulated *Pkd2* recombination in mesenteric arteries of *Pkd2^fl/fl^:Cdh5*-creERT2 mice, but not in arteries of *Pkd2^fl/fl^* mice ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Genomic PCR also amplified an identical product in tamoxifen-treated *Pkd2^fl/fl^* and *Pkd2^fl/fl^:Cdh5*-creERT2 mouse arteries due to *Pkd2* in cells such as smooth muscle, where DNA would not undergo recombination ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib4]).

Western blotting was performed to quantify proteins in lysate collected from second- through fifth-order mesenteric artery branches. PKD2 protein in mesenteric arteries of tamoxifen-treated *Pkd2^fl/fl^:Cdh5*-creERT2 mice was \~ 67.2% of that in tamoxifen-treated *Pkd2^fl/fl^* controls ([Figure 1A,B](#fig1){ref-type="fig"}). This reduction in total arterial protein is expected given that smooth muscle cells, which also express PKD2, are far more abundant than endothelial cells in vessels of this size ([@bib4]). These data are also consistent with our previous observation that smooth muscle-specific PKD2 knockout reduced total mesenteric arterial wall PKD2 protein by \~ 75% ([@bib4]). In contrast, SK3, IK, TRPV4, Piezo1, GPR68 and PKD1 (polycystin-1, PC-1), which can form a complex with PKD2 ([@bib42]; [@bib53]), were similar in arteries of both genotypes ([Figure 1a and b](#fig1){ref-type="fig"}). Immunofluorescence demonstrated that PKD2 protein was present in endothelial cells of intact arteries from tamoxifen-treated *Pkd2^fl/fl^* mice, but absent in endothelial cells of tamoxifen-treated *Pkd2^fl/fl^:Cdh5*-creERT2 mice ([Figure 1C](#fig1){ref-type="fig"}). These results indicate that PKD2 is expressed in endothelial cells and suggest that tamoxifen treatment of *Pkd2^fl/fl^:Cdh5*-creERT2 mice abolishes PKD2 protein. Tamoxifen-treated *Pkd2^fl/fl^:Cdh5*-creERT2 mice will thus be referred to as *Pkd2* ecKO mice. Tamoxifen-treated *Pkd2^fl/fl^* mice were used as controls in all experiments.

![Generation and validation of *Pkd2* ecKO mice.\
(**A**) Representative Western blots illustrating the effect of tamoxifen-treatment of *Pkd2^fl/fl^* and *Pkd2^fl/fl^: Cdh5*(PAC)-creERT2 mice on PKD2, PKD1, Piezo1, GPR68, eNOS, SK3, IK and TPRV4, proteins in mesenteric arteries. (**B**) Mean data for proteins in mesenteric arteries of tamoxifen-treated *Pkd2^fl/fl^: Cdh5*(PAC)-creERT2 mice when compared to those in tamoxifen-treated *Pkd2^fl/fl^* mice. n = 3--8. \* indicates p\<0.05 versus *Pkd2^fl/fl^*. (**C**) *En-fac*e immunofluorescence imaging illustrating that PKD2 protein (Alexa Fluor 555) is abolished in endothelial cells of mesenteric arteries in tamoxifen-treated *Pkd2^fl/fl^: Cdh5*(PAC)-creERT2 mice (representative of 6 mesenteric arteries). CD31 (Alexa Fluor 488) and DAPI are also shown. Scale bars = 50 µm.](elife-56655-fig1){#fig1}

Endothelial cell PKD2 channels contribute to flow-, but not ACh-, mediated vasodilation {#s2-2}
---------------------------------------------------------------------------------------

To investigate physiological functions of endothelial cell PKD2 channels, diameter responses to vasoactive stimuli were measured in pressurized (80 mmHg) third-order mesenteric arteries of *Pkd2*^fl/fl^ and *Pkd2* ecKO mice. Vasodilation to ACh, a muscarinic receptor agonist, was similar in control and *Pkd2* ecKO arteries, suggesting that endothelial cell PKD2 channels do not contribute to this response ([Figure 2A and C](#fig2){ref-type="fig"}). Repetitive intravascular flow (15 dyn/cm^2^) stimuli produced sustained, reproducible and fully reversible vasodilation in pressurized (80 mmHg) mesenteric arteries ([Figure 2---figure supplement 2A--D](#fig2s2){ref-type="fig"}). In pressurized *Pkd2* ecKO arteries, mean vasodilation to single on-off flow stimuli were \~35.1% of those in *Pkd2*^fl/fl^ arteries ([Figure 2B and C](#fig2){ref-type="fig"}). Endothelial cell-denudation abolished vasodilation to both flow and ACh ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). In contrast, endothelial denudation did not alter dilation to sodium nitroprusside, a NO donor, indicating that smooth muscle function was not altered by this procedure ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}). To determine the range over which endothelial cell PKD2 channels function, we measured vasoregulation to flow rates that produced shear stress between 3 and 35 dyn/cm^2^. Cumulative increases in flow caused progressive dilation in *Pkd2*^fl/fl^ arteries, with a maximum at 27 dyn/cm^2^ ([Figure 2D,E](#fig2){ref-type="fig"}). Further increasing flow partially reduced this maximal vasodilatory response ([Figure 2D and E](#fig2){ref-type="fig"}). Flow stimulated less vasodilation in *Pkd2* ecKO arteries over the range studied ([Figure 2D,E](#fig2){ref-type="fig"}; [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Specifically, flow-mediated vasodilation was between \~ 45.5% and 60.1% of that in *Pkd2^fl/fl^* arteries, regardless of rate ([Figure 2D and E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). These data indicate that endothelial cell PKD2 channels function over a broad flow range to stimulate vasodilation in pressurized arteries.

![PKD2 channels contribute to intravascular flow-, but not ACh-, mediated vasodilation.\
(**A**) Original traces illustrating responses to ACh (10 µM) and Ca^2+^-free solution (passive diameter) in pressurized (80 mmHg) mesenteric arteries from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**B**) Original trace of flow-mediated dilation in pressurized (80 mmHg) mesenteric arteries from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**C**) Mean diameter changes in response to flow (15 dyn/cm^2^) or ACh (10 µM). \*p\<0.05 vs. *Pkd2^fl/fl^*. n = 8 for each. \# p\<0.05 vs. flow in the same genotype. (**D**) Original traces illustrating diameter responses to stepwise increases in intravascular flow in pressurized (80 mmHg) mesenteric arteries from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**E**) Mean data. The *Pkd2*-sensitive component of flow-mediated vasodilation is illustrated in blue. \*p\<0.05 vs. *Pkd2^fl/fl^*. n = 5 for *Pkd2^fl/fl^*, n = 4 for *Pkd2* ecKO.](elife-56655-fig2){#fig2}

Experiments were performed to examine the hypothesis that endothelial cell PKD2 channel knockout modifies smooth muscle cell contractility, thereby indirectly altering responses to flow. An increase in extracellular potassium (60 mm K^+^) or intravascular pressure (80 mmHg) similarly constricted arteries of *Pkd2^fl/fl^* and *Pkd2* ecKO mice, indicating that endothelial cell PKD2 channels or their knockout does not influence depolarization-induced vasoconstriction or myogenic tone, respectively ([Figure 2---figure supplement 4A--D](#fig2s4){ref-type="fig"}). Similarly, arterial passive diameter, determined by removal of extracellular Ca^2+^ from the bath solution, was similar in *Pkd2*^fl/fl^ and *Pkd2* ecKO arteries ([Figure 2---figure supplement 4E](#fig2s4){ref-type="fig"}). Thus, knockout of endothelial cell PKD2 channels does not modify smooth muscle cell function.

Endothelial cell PKD2 channels contribute to flow-mediated arterial hyperpolarization {#s2-3}
-------------------------------------------------------------------------------------

To investigate mechanisms by which endothelial cell PKD2 channels regulate contractility, membrane potential was measured in pressurized mesenteric arteries using glass microelectrodes. At 10 mmHg, the mean membrane potential of *Pkd2^fl/fl^* and *Pkd2* ecKO arteries were similar at \~ −62.1 and −61.1 mV, respectively ([Figure 3A,B](#fig3){ref-type="fig"}). Increasing intravascular pressure to 80 mmHg similarly depolarized *Pkd2^fl/fl^* and *Pkd2* ecKO arteries by \~ 19.3 and 17.7 mV, respectively ([Figure 3A,B](#fig3){ref-type="fig"}). Intravascular flow stimulated a mean hyperpolarization of \~ 11 mV in *Pkd2*^fl/fl^ arteries ([Figure 3A,B](#fig3){ref-type="fig"}). In contrast, flow only hyperpolarized *Pkd2* ecKO arteries by \~ 3 mV, or \~ 25.5% of that in controls ([Figure 3A,B](#fig3){ref-type="fig"}). These data suggest that flow modulates PKD2 channels in endothelial cells, leading to arterial hyperpolarization and vasodilation.

![EC PKD2 channels contribute to flow-mediated arterial hyperpolarization.\
(**A**) Original membrane potential recordings obtained from microelectrode impalements in pressurized mesenteric arteries of *Pkd2^fl/fl^* and *Pkd2* ecKO mice at static (10 and 80 mmHg) and with 80 mmHg and flow (15 dyn/cm^2^). All three impalements in *Pkd2^fl/fl^* and *Pkd2* ecKO were from the same two arteries. (**B**) Mean data (*Pkd2^fl/fl^*: 10 mmHg, n = 8; 80 mmHg, n = 10; 80 mmHg + flow, n = 18; *Pkd*2 ecKO: 10 mmHg, n = 7; 80 mmHg, n = 12; 80 mmHg + flow, n = 16). \*p\<0.05 for 80 mmHg static versus 10 mmHg static in same genotype. \# p\<0.05 for 80 mmHg + flow versus 80 mmHg static in the same genotype. and indicates p\<0.05 versus *Pkd2^fl/fl^* under the same condition.](elife-56655-fig3){#fig3}

Flow activates a PKD2-mediated reduction in inward current in endothelial cells {#s2-4}
-------------------------------------------------------------------------------

The contribution of PKD2 channels to currents was investigated in mesenteric artery endothelial cells using patch-clamp electrophysiology. Temporal responses to flow were recorded using the whole-cell configuration with physiological ionic gradients and steady-state voltage of −60 mV. In a static bath, *Pkd2^fl/fl^* endothelial cells generated a mean steady-state inward current of \~−80 pA ([Figure 4A,C](#fig4){ref-type="fig"}). Flow stimulated an initial, transient peak increase in mean inward current of \~−21 pA that was followed by a sustained reduction in inward current that plateaued at \~−11 pA in *Pkd2^fl/fl^* cells ([Figure 4](#fig4){ref-type="fig"}-C). In the continuous presence of flow, the removal of bath Ca^2+^ increased mean inward current to \~−53 pA in *Pkd2^fl/fl^* cells ([Figure 4A,C](#fig4){ref-type="fig"}). In a static bath, mean steady-state inward current was similar in *Pkd2*^fl/fl^ and *Pkd2* ecKO cells ([Figure 4A,C](#fig4){ref-type="fig"}). In contrast, flow activated a transient peak inward current in *Pkd2* ecKO cells that was only \~ 15% of that in *Pkd2^fl/fl^* cells ([Figure 4A,B](#fig4){ref-type="fig"}). Similarly, the sustained flow-mediated reduction in inward current in *Pkd2* ecKO cells was \~ 40% of that in *Pkd2*^fl/fl^ cells ([Figure 4A,C](#fig4){ref-type="fig"}). In the continuous presence of flow, removal of bath Ca^2+^ resulted alsoin a smaller increase in inward current in *Pkd2* ecKO cells than in *Pkd2*^fl/fl^ cells ([Figure 4A,C](#fig4){ref-type="fig"}). Specifically, under flow Ca^2+^ removal increased inward current only \~ 25 pA in *Pkd2* ecKO cells, which was \~ 48.8% of the response in *Pkd2*^fl/fl^ cells ([Figure 4A,C](#fig4){ref-type="fig"}). This differential response to Ca^2+^ removal in *Pkd2^fl/fl^* and *Pkd2* ecKO endothelial cells was due to flow, as inward current in a static condition was similar in cells of both genotypes regardless of whether the bath solution contained Ca^2+^ or was Ca^2+^-free ([Figure 4C](#fig4){ref-type="fig"}). These data demonstrate that flow stimulates a biphasic current response that is composed of an initial transient inward current followed by a sustained Ca^2+^-dependent reduction in inward current in endothelial cells. Data also indicate that PKD2 channels contribute to both of these flow-mediated phases.

![Flow reduces steady-state inward current through a PKD2-mediated, Ca^2+^ influx-dependent mechanism in voltage-clamped mesenteric artery endothelial cells.\
(**A**) Original recordings of steady-state current modulation by flow (10 ml/min) and effect of removing bath Ca^2+^ at −60 mV in endothelial cells from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**B**) Mean data for flow-induced transient inward current. n = 9 for *Pkd2^fl/fl^* and n = 10 for *Pkd2* ecKO. \* indicates p\<0.05 versus *Pkd2^fl/fl^*.(**C**) Mean data for steady-state currents in the presence and absence of flow and in the presence and absence of extracellular Ca^2+^ (*Pkd2^fl/fl^*: static + Ca^2+^, n = 9; static with zero Ca^2+^, n = 6; flow + Ca^2+^, n = 9; flow with zero Ca^2+^, n = 9 and *Pkd*2 ecKO: static + Ca^2+^, n = 9; static with zero Ca^2+^, n = 15; flow + Ca^2+^, n = 8; flow with zero Ca^2+^, n = 8). \*p\<0.05 versus static + Ca^2+^ conditions in the same genotype, and indicates p\<0.05 vs *Pkd2^fl/fl^* under the same condition, \# p\<0.05 versus flow + Ca^2+^ in the same genotype.](elife-56655-fig4){#fig4}

PKD2-mediated Ca^2+^ influx activates SK/IK channels in endothelial cells {#s2-5}
-------------------------------------------------------------------------

Attenuation of the flow-mediated sustained reduction in steady-state inward current by both PKD2 knockout and extracellular Ca^2+^ removal suggests the involvement of IK and SK channels. Under flow, the co-application of apamin and Tram-34, SK and IK channel blockers respectively, increased mean inward current by \~ 23.2 pA in *Pkd2*^fl/fl^ cells ([Figure 5A,B,D](#fig5){ref-type="fig"}). In contrast, the apamin/tram-34-mediated increase in inward current under flow in *Pkd2* ecKO cells was only \~ 11.6 pA or \~50% of that in *Pkd2*^fl/fl^ cells ([Figure 5A,B,D](#fig5){ref-type="fig"}). In a static bath, apamin/Tram-34 produced a far smaller and similar increase in inward current in *Pkd2*^fl/fl^ and *Pkd2* ecKO cells ([Figure 5C,D](#fig5){ref-type="fig"}). These data suggest that flow stimulates PKD2-mediated Ca^2+^ influx that activates SK/IK channels in endothelial cells, leading to a steady-state reduction in inward current.

![Flow-mediated PKD2 channel activation stimulates SK/IK channels in mesenteric artery endothelial cells, leading to vasodilation.\
(**A**) Original recordings of steady-state current modulation by flow (10 ml/min) and flow plus apamin/Tram-34 (300 nM of each) at −60 mV in mesenteric artery ECs from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**B**) Mean data (*Pkd2^fl/fl^*: static, n = 8; flow, n = 8; flow + apamin/Tram-34, n = 7. *Pkd2* ecKO: static, n = 9, flow, n = 10; flow + apamin/Tram-34, n = 9). \* indicates p\<0.05 versus static in the same genotype and p\<0.05 vs *Pkd2^fl/fl^* in the same conditions. \# p\<0.05 versus flow in the same genotype. (**C**) Original recordings of steady-state current modulation by apamin/Tram-34 (300 nM of each) in the absence of flow at −60 mV in ECs from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**D**) Mean data comparing responses to apamin/Tram-34 in static and flow conditions at −60 mV (*Pkd2^fl/fl^*: static, n = 6; flow, n = 7. *Pkd2* ecKO: static, n = 6; flow, n = 9). \*p\<0.05 versus static control. \# p\<0.05 versus static + apamin/Tram-34 in the same genotype. and indicates p\<0.05 for *Pkd2* ecKO vs *Pkd2^fl/fl^* in the same condition.](elife-56655-fig5){#fig5}

Next, we tested the hypothesis that flow-stimulates vasodilation through PKD2-mediated SK/IK channel activation. Apamin/Tram-34 reduced both flow- and ACh -induced vasodilation in *Pkd2*^fl/fl^ arteries to \~ 77% and 57% of those that occurred in the control condition ([Figure 6A,C](#fig6){ref-type="fig"}). Apamin/Tram-34 reduced mean ACh-induced vasodilation to \~ 54% of that in control in *Pkd2* ecKO arteries, which was a similar reduction to that in *Pkd2^fl/fl^* arteries ([Figure 6A,C](#fig6){ref-type="fig"}). In contrast, apamin/Tram-34 did not alter flow-mediated vasodilation in *Pkd2* ecKO arteries ([Figure 6A,C](#fig6){ref-type="fig"}). With static intravascular solution, bath application of apamin/Tram-34 did not alter the diameter of pressurized, myogenic *Pkd2*^fl/fl^ or *Pkd2* ecKO mesenteric arteries, indicating that SK and IK channels are not active in the absence of flow or ACh ([Figure 6B,C](#fig6){ref-type="fig"}). These data indicate that flow stimulates PKD2-mediated SK/IK channel activation in endothelial cells to induce vasodilation. In contrast, ACh stimulates vasodilation via a PKD2-independent SK/IK channel-mediated mechanism.

![PKD2 channels contribute to intravascular flow-mediated SK/IK channel activation and vasodilation.\
(**A**) Representative traces illustrating responses to flow (15 dyn/cm^2^) and flow (15 dyn/cm^2^) + ACh (10 µM) in the presence and absence of apamin/Tram-34 (300 nM of each) in pressurized (80 mmHg) mesenteric arteries from *Pkd2^fl/fl^* and *Pkd2* ecKO mice. (**B**) Representative traces illustrating responses to apamin/Tram-34 (300 nM of each) in the absence of intravascular flow in pressurized (80 mmHg) mesenteric arteries. (**C**) Mean data (*Pkd2^fl/fl^*: flow, n = 5; flow + apamin/Tram-34, n = 5; flow + ACh (10 µM), n = 5; flow + ACh (10 µM) + apamin/Tram-34, n = 5; static + apamin/Tram-34, n = 5. *Pkd2* ecKO: flow, n = 5; flow + apamin/Tram-34, n = 5; flow + ACh (10 µM), n = 5; flow + ACh (10 µM) + apamin/Tram-34, n = 4; static + apamin/Tram-34, n = 5). \* indicates p\<0.05 versus *Pkd2^fl/fl^* in the same condition. \# indicates p\<0.05 for flow + apamin/Tram-34 versus flow in the same genotype. and indicates p\<0.05 for flow + ACh versus flow + ACh + apamin/Tram-34 in the same genotype.](elife-56655-fig6){#fig6}

PKD2 channel activation is essential for flow-mediated eNOS activation in endothelial cells {#s2-6}
-------------------------------------------------------------------------------------------

Flow stimulates nitric oxide synthase (NOS) in endothelial cells, but the significance of PKD2 channels to this activation mechanism is unclear ([@bib16]; [@bib1]; [@bib21]). Phosphorylation of bovine eNOS at serine 1179 and human eNOS at serine 1177 leads to activation ([@bib19]; [@bib7]). Western blotting was performed to measure both eNOS protein phosphorylated at serine 1176 (p-eNOS (S1176)) and total eNOS protein in mouse mesenteric arteries. Intravascular flow (15 dyn/cm^2^, 5 min, 37°C) increased mean p-eNOS (S1176) protein \~ 1.4 fold in *Pkd2*^fl/fl^ arteries, but only \~ 1.08 fold in *Pkd2* ecKO arteries ([Figure 7A,B](#fig7){ref-type="fig"}). In contrast, flow did not alter total eNOS in either genotype ([Figure 7A,B](#fig7){ref-type="fig"}). L-NNA, a NOS inhibitor, reduced flow-mediated vasodilation to \~ 64% of control in pressurized *Pkd2*^fl/fl^ arteries and to \~ 83% of control in *Pkd2* ecKO arteries ([Figure 7C,D](#fig7){ref-type="fig"}). Thus, the L-NNA-induced reduction in flow-mediated vasodilation in *Pkd2* ecKO arteries was \~ 47% of that in *Pkd2^fl/fl^* arteries ([Figure 7C,D](#fig7){ref-type="fig"}). These data indicate that PKD2 channels are key for flow to activate eNOS in endothelial cells and to elicit vasodilation through this mechanism in mesenteric arteries.

![Flow-mediated PKD2 channel activation in ECs stimulates eNOS serine 1176 phosphorylation, leading to vasodilation.\
(**A**) Original Western blots illustrating effects of flow (15 dyn/cm^2^) and *Pkd2* ecKO on p-eNOS (S1176) and total eNOS proteins in *Pkd2^fl/fl^* and *Pkd2* ecKO mesenteric arteries. (**B**) Mean data for flow-induced change (Δ) in proteins. n = 5 for *Pkd2^fl/fl^*. n = 4 for *Pkd2* ecKO. \* indicates p\<0.05 versus static. \# indicates p\<0.05 versus same protein in *Pkd2^fl/fl^*. (**C**) Representative traces demonstrating flow (15 dyn/cm^2^)-mediated vasodilation in pressurized (80 mmHg) mesenteric arteries of *Pkd2^fl/fl^* and *Pkd2* ecKO mice in the presence and absence of L-NNA (10 µM). (**D**) Mean data. n = 10 for *Pkd2^fl/fl^*. n = 5 for *Pkd2* ecKO. \* indicates p\<0.05 versus *Pkd2^fl/fl^* in the same condition. \# indicates p\<0.05 versus flow in the absence of L-NNA (10 µM) in the same genotype.](elife-56655-fig7){#fig7}

*Pkd2* ecKO mice are hypertensive {#s2-7}
---------------------------------

In vitro evidence that endothelial cell PKD2 channels contribute to flow-mediated vasodilation suggests that these proteins may regulate blood pressure. Telemetry measurements were performed using implanted probes to measure systemic blood pressure in *Pkd2^fl/fl^* and *Pkd2* ecKO mice. Diastolic and systolic blood pressures were \~ 9 and 14 mmHg higher, respectively, in *Pkd2* ecKO than *Pkd2^fl/fl^* mice, which translated to a mean arterial pressure (MAP) that was raised by \~ 11% ([Figure 8A,B](#fig8){ref-type="fig"}). Locomotion was similar between genotypes, indicating that the higher blood pressure in *Pkd2* ecKO mice was not due to higher activity ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Echocardiography measurements indicated that cardiac output, fractional shortening, ejection fraction and heart rate were all similar in *Pkd2^fl/fl^* and *Pkd2* ecKO mice ([Figure 8C--F](#fig8){ref-type="fig"}). Proximal tubule diameter and glomerular area were also similar in kidneys of *Pkd2^fl/fl^* and *Pkd2* ecKO mice, indicating no renal dysfunction ([Figure 8G--I](#fig8){ref-type="fig"}). These results demonstrate that flow stimulates PKD2 channels in endothelial cells to induce vasodilation and reduce systemic blood pressure.

![*Pkd2* ecKO elevates systemic blood pressure, but does not alter cardiac function or kidney histology.\
(**A**) Mean diastolic and systolic blood pressures in *Pkd2^fl/fl^* and *Pkd*2 ecKO mice (n = 5 for each). \* indicates p\<0.05 versus *Pkd2^fl/fl^*. (**B**) Mean arterial blood pressure (MAP) (n = 5 for each). \* indicates p\<0.05 versus *Pkd2^fl/fl^*. (**C--F**) Mean echocardiography data. Heart rate (HR), Cardiac output (CO), fractional shortening (FS) and ejection fraction (EF) (n = 5 *Pkd2^fl/fl^* and n = 10 for *Pkd2* ecKO). (**G**) Representative images of H and E stained kidney cortex used for histological assessment. Scale bars = 100 µm. (**H**) Mean proximal tubule length (n = 15 proximal tubules measured for each group from three individual mice). (**I**) Mean glomeruli surface area (n = 75 glomeruli measured per group from three individual mice).](elife-56655-fig8){#fig8}

Discussion {#s3}
==========

Here, we investigated mechanisms of regulation and physiological functions of PKD2 channels in endothelial cells by using an inducible, conditional knockout mouse model. Endothelial cell PKD2 knockout robustly inhibits flow-mediated vasodilation, but does not alter dilation to ACh, in resistance-size arteries, suggesting stimulus-specific signaling and function. Flow stimulates PKD2 channels, leading to both Ca^2+^ influx-dependent SK/IK channel activation and eNOS phosphorylation and activation in endothelial cells ([Figure 9](#fig9){ref-type="fig"}). These mechanisms induce arterial hyperpolarization and vasodilation. Endothelial cell PKD2 channel knockout increased both diastolic and systolic blood pressure in mice, without effects on cardiac function or kidney anatomy. Thus, by coupling intravascular flow to vasodilation, endothelial cell PKD2 channels reduce blood pressure.

![Schematic illustration of the mechanisms by which endothelial cell PKD2 channels elicit flow-mediated vasodilation.](elife-56655-fig9){#fig9}

Global knockout of a gene can lead to compensatory expression of other genes that produce contrasting and contradictory results to those expected from studies on isolated cells and tissues. Whether endothelial cell TRP channels are functional could not be determined from global TRPC6, TRPM4 and TRPV4 channel knockout mice, which generated complex findings associated with compensatory mechanisms ([@bib11]; [@bib34]; [@bib6]; [@bib40]). Global knockout of TRPM4, which is expressed in multiple cell types, including arterial smooth muscle, increased catecholamine secretion that elevated blood pressure in mice ([@bib34]; [@bib10]). TRPC6 knockout resulted in upregulation of constitutively active TRPC3 channels in arterial smooth muscle cells that caused vasoconstriction and elevated blood pressure ([@bib6]). Global knockout of TRPV4 channels, which are expressed in both arterial smooth muscle cells and endothelial cells, resulted in either the same or lower blood pressure than controls ([@bib11]; [@bib40]). Here, inducible, endothelial cell-specific PKD2 knockout did not alter the expression of PKD1, Piezo1, GPR68, SK3, IK or TRPV4 channels in mesenteric arteries. Flow stimulated plasma membrane Ca^2+^ influx that activated SK/IK channels, producing a steady-state reduction in inward current in *Pkd2*^fl/fl^ mouse endothelial cells. PKD2 knockout reduced both the flow-mediated transient inward current and the steady-state reduction in inward current that occurred, in part, due to Ca^2+^-dependent SK/IK channel activation. Flow elevated intracellular Ca^2+^ concentration and activated eNOS in a Ca^2+^/calmodulin--dependent manner ([@bib16]; [@bib36]; [@bib65]). The ion channel(s) responsible for these Ca^2+^-dependent signaling mechanisms were unclear. Here, we show that PKD2 channels are essential to both flow-mediated Ca^2+^ influx that activates SK/IK channels and to eNOS activation. PKD2 channel properties have been debated for almost two decades, particularly their ionic permeability. Recent evidence suggests that PKD2 homotetramers are voltage-dependent, outwardly rectifying and primarily permeant to Na^+^ and K^+^, with low Ca^2+^ permeability ([@bib46]; [@bib59]). PKD1 and PKD2 in a 1 to 3 ratio, respectively, can also form a heterotetrameric channel that is far more permeant to Ca^2+^ than PKD2 homotetramers ([@bib59]; [@bib48]; [@bib66]; [@bib63]). Whether flow stimulates PKD2 homotetramers and/or a PKD1/PKD2 heterotetramers to generate the Ca^2+^ signal that activates SK/IK channels remains to be established. PKD2 has also been proposed to interact with TRPC1, TRPC3, TRPC5, TRPC7 and TRPV4 channels, but whether heterotetrameric channel formation occurs between these different proteins in native endothelial cells is poorly understood ([@bib37]; [@bib54]; [@bib27]; [@bib51]; [@bib9]; [@bib8]). Future studies should test these hypotheses.

Increasing intravascular flow produced progressive vasodilation, with the relative contribution of endothelial cell PKD2 channels to this response approximately 50%, regardless of the magnitude of shear stress. These results indicate that PKD2 channel activity is flow-dependent and show that PKD2 channels function over a broad range of shear stress to elicit vasodilation. PKD2 channels do not appear to be inherently flow-sensitive. Potential mechanisms by which flow stimulates PKD2 channels include coupling to PKD1, regulation by microtubules and/or the actin cytoskeleton, and through interaction with TRPV4 and TRPC1 ([@bib9]; [@bib29]; [@bib23]; [@bib39]). PKD2 channel knockout did not abolish flow-mediated current modulation in endothelial cells or vasodilation in pressurized arteries, suggesting that PKD2 channel-independent mechanisms also contribute to these responses. A previous study demonstrated that flow activates Piezo1 channels in endothelial cells, leading to vasodilation and a reduction in blood pressure ([@bib58]). In contrast, another study published that endothelial cell Piezo1 does not regulate blood pressure during inactivity, but is activated by an increase in flow during exercise, resulting in arterial depolarization and vasoconstriction ([@bib44]). Global knockout of GPR68, a class A rhodopsin-like G protein-coupled receptor, reduced flow-mediated vasodilation in third-order mesenteric arteries, but did not alter effects of flow in first- or second-order mesenteric arteries where it is not expressed ([@bib61]). Other proposed flow-mediated mechanisms include those via TRPV4, angiotensin type II, histamine, and bradykinin type two receptors, although recombinant expression of these proteins has also been shown to not produce flow-mediated responses ([@bib64]; [@bib5]; [@bib35]; [@bib43]). Signaling mechanism described include the release of ATP, which binds in an autocrine manner to purinergic receptors, adrenomedullin, acting via cell surface receptors containing CALCRL, and ACh that is released by organic cation transporters and activates muscarinic receptors ([@bib58]; [@bib24]; [@bib60]). These pathways can also involve eNOS activation ([@bib58]; [@bib24]). Which of these mechanisms are PKD2-dependent and which are PKD2-independent remains to be established.

Endothelial cell *Pkd2* knockout attenuated flow-mediated vasodilation, but did not alter vasodilation to ACh, indicating differential signaling mechanisms. Intracellular signals and kinases that regulate PKD2 channels in endothelial cells are poorly understood. As such, it is not clear whether signaling mechanisms activated by muscarinic receptors are incapable of activating PKD2 channels. Muscarinic receptor agonists activate TRPV4 channels, leading to Ca^2+^ influx, and promote endoplasmic reticulum Ca^2+^ release, both of which can stimulate SK and IK channels and eNOS to produce vasodilation ([@bib47]; [@bib15]; [@bib17]). The relative proportion of each of these pathways to muscarinic receptor-mediated signaling differs depending on the arterial bed that is studied. Here, we show that PKD2 channel activation also stimulates IK/SK channels and eNOS. Thus IK/SK and eNOS are common downstream targets for both TRPV4 and PKD2 channels. A reasonable explanation for differential signaling elicited by flow and muscarinic receptors is that flow activates PKD2 channels in endothelial cells via a compartmentalized mechanism that excludes signaling from muscarinic receptors. Homozygous knockout of *Pkd2* is lethal in mice, precluding study of the global absence of this gene product on vascular function. ACh-induced vasodilation was attenuated due to a decrease in the availability of nitric oxide in mesenteric arteries of *Pkd2* heterozygous (*Pkd2^+/-^*) mice aged between 16 and 20 weeks ([@bib3]). This result is in marked contrast to observations we made here where ACh-induced vasodilation was similar in mesenteric arteries of *Pkd2*^fl/fl^ and *Pkd2* ecKO mice. These different observations likely reflect the effects of studying short-term, endothelial cell specific PKD2 knockout versus a global and prolonged reduction in PKD2 protein that was present since gestation.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) occurs due to mutations in *Pkd1* or *Pkd2* and is the most prevalent monogenic human disease worldwide, affecting 1 in 400--1000 individuals ([@bib52]). More than 275 variants in human *Pkd2* have been identified (<http://pkdb.pkdcure.org>). Although ADPKD is characterized by the appearance of renal cysts, patients can develop hypertension prior to any kidney dysfunction ([@bib52]; [@bib55]; [@bib33]). Here, short-term endothelial cell PKD2 knockout increased systemic blood pressure without inducing cardiac or renal abnormalities. These data suggest that ADPKD patients may develop hypertension due to dysfunctional endothelial cell PKD2 channels and attenuated flow-mediated vasodilation. During an increase in sustained blood flow, human ADPKD patients display loss of nitric oxide release and an associated reduction in endothelium-dependent dilation in conduit arteries, consistent with the results obtained in our mouse model ([@bib31]) As the polycystin mutation was global in these human subjects, it was not clear if the vascular deficiency was due to dysfunctional signaling in endothelial cells or another cell type that regulates endothelial cell function. Prolonged polycystin dysregulation in ADPKD patients may alter responses to a wide variety of other stimuli that were not studied. Future studies should investigate the effects of ADPKD-associated *Pkd2* mutations on endothelial cell function, arterial contractility and systemic blood pressure. Our demonstration that endothelial cell PKD2 channels contribute to flow-mediated vasodilation and reduce blood pressure is a step forward in understanding the physiological significance of this protein and its dysfunction in patients with ADPKD and other cardiovascular diseases.

In summary, using an inducible, conditional *Pkd2* knockout mouse, we demonstrate that intravascular flow stimulates PKD2 channels in endothelial cells, leading to Ca^2+^-dependent SK/IK channel and eNOS activation, arterial hyperpolarization, vasodilation and a reduction in systemic blood pressure. These results indicate that endothelial cell PKD2 channels are a major mechanistic component of functional flow-sensing in the vasculature.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                               Designation                                                   Source or reference         Identifiers                                                                                                                                  Additional\
  (species) or resource                                                                                                                                                                                                                                                              information
  ------------------------------------------- ------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Strain, strain background (*M. musculus*)   Pkd2^fl/fl^                                                   Baltimore PKD Core Center   PMID:[20862291](https://www.ncbi.nlm.nih.gov/pubmed/20862291)                                                                                Mice with *Pkd2* gene flanked by *loxP* regions.

  Strain, strain background (*M. musculus*)   *Cdh5*(PAC)-creERT2                                           Cancer Research UK          RRID:[MGI:3848984](https://scicrunch.org/resolver/MGI:3848984)                                                                               Mice with tamoxifen-inducible Cre recombinase that is expressed\
                                                                                                                                                                                                                                                                                     specifically in endothelial cells.

  Strain, strain background (*M. musculus*)   Pkd2^fl/fl^: *Cdh5*(PAC)-creERT2                              This paper                                                                                                                                                               Mouse line created in-house by mating *Pkd2^fl/fl^* with *Cdh5*(PAC)-creERT2. Mice with inducible endothelial cell-specific deletion of PKD2.

  Antibody                                    Anti-PKD2\                                                    Baltimore PKD Core          Rabbit mAB 3374 CT-14/4                                                                                                                      IF 1:200 dilution
                                              (rabbit polyclonal)                                                                                                                                                                                                                    

  Antibody                                    Anti-PKD2 (mouse monoclonal)                                  Santa Cruz                  Cat\# sc-47734\                                                                                                                              WB 1:100 dilution
                                                                                                                                        RRID:[AB_672380](https://scicrunch.org/resolver/AB_672380)                                                                                   

  Antibody                                    Anti-PKD1 (mouse monoclonal)                                  Santa Cruz                  Cat\# sc-28331\                                                                                                                              WB 1:100 dilution
                                                                                                                                        RRID:[AB_672377](https://scicrunch.org/resolver/AB_672377)                                                                                   

  Antibody                                    Anti-Piezo1 (rabbit polyclonal)                               Proteintech                 Cat 15939--1-AP.                                                                                                                             WB 1:100 dilution

  Antibody                                    Anti-SK3 antibody                                             Abcam                       Cat\# ab28631\                                                                                                                               WB 1:100 dilution
                                                                                                                                        RRID:[AB_775888](https://scicrunch.org/resolver/AB_775888)                                                                                   

  Antibody                                    Anti-IK1 Antibody (D-5) (mouse monoclonal)                    Santa Cruz                  Cat\# sc-365265\                                                                                                                             WB 1:100 dilution
                                                                                                                                        RRID:[AB_10841432](https://scicrunch.org/resolver/AB_10841432)                                                                               

  Antibody                                    Anti-eNOS (mouse monoclonal)                                  Abcam                       Cat\# ab76198\                                                                                                                               WB 1:100 dilution
                                                                                                                                        RRID:[AB_1310183](https://scicrunch.org/resolver/AB_1310183)                                                                                 

  Antibody                                    Anti-p-eNOS (rabbit polyclonal)                               Cell signaling Technology   Cat\# 9571\                                                                                                                                  WB 1:100 dilution
                                                                                                                                        RRID:[AB_329837](https://scicrunch.org/resolver/AB_329837)                                                                                   

  Antibody                                    Anti-GPR68                                                    NOVUS Biologicals           Cat\# NBP2-32747                                                                                                                             WB 1:100 dilution

  Antibody                                    Anti-TRPV4\                                                   Millipore Sigma             Cat\# MABS466                                                                                                                                WB 1:100 dilution
                                              (clone 1B2.6) (mouse monoclonal)                                                                                                                                                                                                       

  Antibody                                    Anti-Actin (mouse monoclonal)                                 Millipore Sigma             Cat\# MAB1501\                                                                                                                               WB 1:5000 dilution
                                                                                                                                        RRID:[AB_2223041](https://scicrunch.org/resolver/AB_2223041)                                                                                 

  Antibody                                    Alexa 555 secondary antibodies (anti rabbit and anti mouse)   Thermo Fisher               Cat\# A-21429\                                                                                                                               IF 1:400 dilution
                                                                                                                                        (RRID:[AB_141761](https://scicrunch.org/resolver/AB_141761)) and \# A-31570 (RRID:[AB_2536180](https://scicrunch.org/resolver/AB_2536180))   

  Antibody                                    Alexa 488 secondary antibodies (anti rat)                     Thermo Fisher               Cat\# A-21470\                                                                                                                               IF 1:400\
                                                                                                                                        RRID:[AB_2535873](https://scicrunch.org/resolver/AB_2535873)                                                                                 dilution

  Other                                       Nuclear staining (DAPI)                                       Thermo Fisher               Cat\# 3571\                                                                                                                                  IF 1:1000 dilution
                                                                                                                                        RRID:[AB_2307445](https://scicrunch.org/resolver/AB_2307445)                                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

All procedures were approved by the Animal Care and Use Committee of the University of Tennessee (protocol 17--068.0). *Pkd2^fl/fl^* mice were obtained from the Baltimore PKD Core Center. *Cdh5*(PAC)-creERT2 mice were a kind gift from Cancer Research UK ([@bib57]). *Pkd2^fl/fl^* mice with *loxP* sites flanking exons 11--13 of the *Pkd2* gene were obtained from the John Hopkins PKD Core. *Pkd2^fl/fl^* mice were crossed with tamoxifen-inducible endothelial cell-specific Cre mice (Cdh5(PAC)-CreERT2, Cancer Research UK) to generate *PKD2^fl/fl^:Cdh5(PAC)-CreERT2* mice. Male *Pkd2^fl/fl^:Cdh5(PAC)-CreERT2* or *Pkd2^fl/fl^* mice (8--14 weeks of age) were injected with tamoxifen (1 mg/ml, i.p.) once per day for 5 days and studied 7--14 days after the last injection.

Tissue preparation and endothelial cell isolation {#s4-2}
-------------------------------------------------

Male mice were euthanized with isoflurane (1.5%), followed by decapitation. Mesenteric artery branches from first- to fifth-order were removed, cleaned of adventitial tissue and placed into ice-cold physiological saline solution (PSS) that contained (in mM): 112 NaCl, 6 KCl, 24 NaHCO~3~, 1.8 CaCl~2~, 1.2 MgSO~4~, 1.2 KH~2~PO~4~ and 10 glucose, gassed with 21% O~2~, 5% CO~2~ and 74% N~2~ to pH 7.4. Endothelial cells were dissociated by introducing endothelial cell basal media (Endothelial cell GM MV2, Promocell) containing 2 mg/ml collagenase type 1 (Worthington Biochemical) into the arterial lumen and left to incubate for 30--40 min at 37°C. Cells isolated from mesenteric arteries contain multiple different types that exhibit similar visual phenotypes upon enzymatic isolation. To obtain a population of endothelial cells, cell isolate was placed into endothelial cell basal media containing growth supplements (Promocell) that support only endothelial cell survival. Endothelial cells were then studied \< 5 days later.

Genomic PCR {#s4-3}
-----------

Genomic DNA was isolated from mesenteric arteries using a Purelink Genomic DNA kit (Thermo Fisher Scientific). Reaction conditions used are outlined in the Baltimore PKD Center genotyping protocol (<http://baltimorepkdcenter.org/mouse/PCR%20Protocol%20for%20Genotyping%20PKD2KO%20and%20PKD2%5Eneo.pdf>). Genotyping was performed using a 3-primer strategy, with primers a (5'-CCTTTCCTCTGGTTCTGGGGAG), b (5'-GTTGATGCTTAGCAGATGATGGC) and c (5'-CTGACAGGCACCTACAGAACAGTG) used to identify floxed and deleted alleles.

Western blotting {#s4-4}
----------------

Mesenteric artery segments comprising second- to fifth-order vessels were used for Western blotting. For experiments examining flow-mediated regulation of NOS and p-eNOS proteins, a glass cannula was inserted into the first-order branch of a mesenteric artery segment and flow introduced through to fifth-order arteries. Proteins were separated on 7.5% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes. Membranes were blocked with 5% milk and incubated with one of the following primary antibodies: Piezo1 (Proteintech), PKD1 (Santa Cruz), PKD2 (Santa Cruz), SK3 (Abcam), eNOS (Abcam), IK (Alomone), p-eNOS (Cell Signaling), GPR68 (NOVUS), TRPV4 (MilliporeSigma) or actin (MilliporeSigma) overnight at 4°C. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature. Protein bands were imaged using a ChemiDoc Touch Imaging System (Bio-Rad), quantified using ImageJ software and normalized to actin.

*En-face* arterial immunofluorescence {#s4-5}
-------------------------------------

Arteries were cut longitudinally and fixed with 4% paraformaldehyde in PBS for 1 hr. Following a wash in PBS, arteries were permeabilized with 0.2% Triton X-100, blocked with 5% goat serum and incubated overnight with PKD2 primary antibody (Rabbit mAB 3374 CT-14/4: Baltimore PKD Center) at 4°C. Arteries were then incubated with Alexa Fluor 555 rabbit anti-mouse secondary antibody (1:400; Molecular Probes) and 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI) (1:1000; Thermo Scientific) for 1 hr at room temperature. Arteries were washed with PBS and mounted in 80% glycerol solution. DAPI and Alexa 555 were excited at 350 nm and 555 nm with emission collected at ≤ 437 nm and ≥ 555 nm, respectively, using a Zeiss LSM 710 laser-scanning confocal microscope.

Pressurized artery myography {#s4-6}
----------------------------

Experiments were performed using isolated third- and fourth-order mesenteric arteries using PSS gassed with 21% O~2~/5% CO~2~/74% N~2~ (pH 7.4). Arterial segments 1--2 mm in length were cannulated at each end in a perfusion chamber (Living Systems Instrumentation) continuously perfused with PSS and maintained at 37°C. Intravascular pressure was altered using a Servo pump model PS-200-P (Living systems) and monitored using pressure transducers. Following development of stable myogenic tone, luminal flow was introduced during experiments using a P720 peristaltic pump (Instech). Arterial diameter was measured at 1 Hz using a CCD camera attached to a Nikon TS100-F microscope and the automatic edge-detection function of IonWizard software (Ionoptix). Myogenic tone was calculated as: 100 x (1-D~active~/D~passive~) where D~active~ is active arterial diameter and D~passive~ is the diameter determined in the presence of Ca^2+^-free PSS supplemented with 5 mM EGTA.

Pressurized artery membrane potential measurements {#s4-7}
--------------------------------------------------

Membrane potential was measured by inserting sharp glass microelectrodes (50--90 MΩ) filled with 3 M KCl into the adventitial side of pressurized third- and fourth-order mesenteric arteries. Membrane potential was recorded using a WPI FD223a amplifier and digitized using a MiniDigi 1A USB interface, pClamp 9.2 software (Axon Instruments) and a personal computer. Criteria for successful intracellular impalements were: ([@bib56]) a sharp negative deflection in potential on insertion; ([@bib14]) stable voltage for at least 1 min after entry; ([@bib28]) a sharp positive voltage deflection on exit from the recorded cell and ([@bib22]) a \< 10% change in tip resistance after the impalement.

Patch-clamp electrophysiology {#s4-8}
-----------------------------

The conventional whole-cell configuration was used to measure steady-state currents in isolated endothelial cells at a holding potential of −60 mV. The bath solution contained (in mM): NaCl 134, KCl 6, HEPES 10, MgCl~2~ 1, CaCl~2~ 2 and glucose 10 (pH 7.4, NaOH). Ca^2+^-free bath solution was the same composition as bath solution except Ca^2+^ was omitted and 1 mM EGTA added. The pipette solution contained (in mM): K aspartate 110, KCl 30, HEPES 10, glucose 10 and EGTA 1, with total MgCl~2~ and CaCl~2~ adjusted to give free concentrations of 1 mM and 200 nM, respectively. Free Mg^2+^ and Ca^2+^ were calculated using WebmaxC Standard (<http://www.stanford.edu/~cpatton/webmaxcS.htm>). The osmolarity of solutions was measured using a Wescor 5500 Vapor Pressure Osmometer (Logan, UT, USA). Currents were filtered at 1 kHz and digitized at 5 kHz using an Axopatch 200B amplifier and Clampex 10.4 (Molecular Devices. Offline analysis was performed using Clampfit 10.4. Flow-activated transient inward current was measured at its peak in each cell. Steady-state inward currents were calculated as the average of at least 45 s of continuous data.

Telemetric blood pressure and locomotion measurements {#s4-9}
-----------------------------------------------------

Telemetric blood pressure recordings were performed by the University of Cincinnati Mouse Metabolic Phenotyping Center. Briefly, transmitters (PA-C10, Data Sciences International) were implanted subcutaneously into anesthetized mice, with the sensing electrode placed in the aorta via the left carotid artery. Blood pressures were measured prior, during and following tamoxifen injections (1 mg/ml, i.p) using a PhysioTel Digital telemetry platform (Data Sciences International). Dataquest A.R.T. software was used to acquire and analyze data.

Echocardiography {#s4-10}
----------------

Age- and sex-matched mice were anesthetized with isoflurane and placed on a warm pad on a recording stage of a Vevo 2100 ultrasound machine. The anterior chest was shaved and ultrasound coupling gel applied. Electrodes were connected to each limb and an electrocardiogram was recorded. Two-dimensional (short axis-guided) M-mode measurements were taken at the level of the papillary muscles using an 18--32 MHz MS400 transducer, as previously described ([@bib41]). Images were also recorded in the parasternal long-axis. For analysis purposes, three or more beats were averaged using measurements within the same HR interval (450 ± 50 bpm) for analysis.

Kidney histology {#s4-11}
----------------

Kidney sections were stained with H and E and examined by Probetex, Inc (San Antonio, Texas). Briefly, image analysis was performed to measure glomerular size and tubular cross-sectional diameter. Glomerular size was measured by tracing the circumference of each of 25 random glomeruli and surface area calculated using the polygonal area tool of Image-Pro 4.5 image analysis software calibrated to a stage micrometer. Tubular size was measured using the linear length tool of Image-Pro 4.5 imaging software. The tracing tool was applied at the diameter of cross-sectional profiles of 5 proximal tubules/image (total of 25/section). Glomerular and tubular images were calibrated to a stage micrometer and data was transferred to an Excel spreadsheet and statistical analysis performed by Excel analysis pack.

Statistical analysis {#s4-12}
--------------------

OriginLab and GraphPad InStat software were used for statistical analyses. Values are expressed as mean ± SEM. Student t-test was used for comparing paired and unpaired data from two populations and ANOVA with Holm-Sidak post hoc test used for multiple group comparisons. p\<0.05 was considered significant. Power analysis was performed to verify that the sample size gave a value of \> 0.8 if P was \> 0.05. Kidney histology, blood pressure and cardiac function experiments were all done single blind, wherein the person performing both the experiments and analysis of the results was not aware of the mouse genotype.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Intravascular flow stimulates PKD2 (polycystin-2) channels in endothelial cells to reduce blood pressure\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by MacKay et al. uses an endothelial cell (EC)-specific polycystin-2 (*Pkd2*)-knockdown model that the authors developed to establish that the transient receptor potential family member, TRPP1, also known as PKD2, contributes to flow-induced dilation in mesenteric resistance arteries via an IK/SK channel- and NO-dependent mechanism. The authors further show that blood pressure is elevated in *Pkd2* ecKD mice in the absence of alterations in other cardiovascular metrics or kidney function, suggesting a role for this channel in regulating vasodilation in vivo under baseline conditions. The experimental approach is appropriate, the results are generally logically presented, and the conclusions follow from the results. Remaining experimental issues are relatively minor, and there are some additional concerns regarding the presentation.

Essential revisions:

1\) The authors should comment on the potential mechanism by which flow increases PKD2 activity.

2\) What do the authors predict the Po-shear stress relationship of PKD2 would be and how would it influence Figure 2E? How would it compare to other flow sensitive channels?

3\) This lab reported PKD2 expression smooth muscle cells and that these channels contribute to the development of myogenic tone. Together with the new data, that would imply that PKD2 channels are activated by stretch and flow. Are these modes of activation synergistic? Also, how would the function of PKD2 in smooth muscle and endothelial cells would balance to produce a specific vessel response to a change in pressure and flow?

4\) It would be helpful to include in Figure 2E a third data set showing the PKD2-sensitive component of flow induced changes in diameter.

5\) The observation that loss of ecPKD2 channels does not alter the response of ECs to ACh. How are these channels modulated by kinases such by mediators of the muscarinic response? Perhaps PKD2 channels are not expressed at distances sufficiently close to AKAPs to be modulated by this signaling pathway.

6\) The approximate \~33% reduction in PKD2 expression in EC-specific tamoxifen-treated *Pkd2^fl/fl^:Cdh5(PAC)-creERT2* mice (Western blotting) seems pretty meager. The description of the methods on this point implies that these data were obtained from whole artery segments, including the smooth muscle layer, which could account for the seemingly modest knockdown. Although immunohistochemistry results suggest a more robust knockdown, these results are qualitative for the most part. In any case, methods used to prepare samples should be clarified and possible explanations for the underwhelming knockdown effect in whole artery segments should be discussed.

7\) Data shown in Figures 4 and 5, taken together with data in Figure 6, suggest that IK/SK and NO should make additive contributions to flow-induced dilation. (There is no obvious mechanism for these two pathways to act in series.) Does application of apamin/Tram-34 together with L-NNA further reduce flow-induced dilation compared with either intervention alone? These data should be included if available.

Presentation issues:

1\) The authors refer to their model as an EC-specific *Pkd2* knockout. It isn\'t. It\'s an EC-specific knockdown (ecKD) model-a fact that might contribute to observed incomplete effects (in addition to the suggested involvement of PKD2-independent mechanisms). Descriptions in the text should be modified to reflect this.

2\) It\'s not clear from Figure 4A and B (or the Materials and methods) at what point in the traces transient responses were measured. What is clear from Figure 4A is that the direction of the response in *Pkd2*-ecKO arteries at a point that would appear to constitute a transient response is opposite that in *Pkd2^fl/fl^* arteries. These data suggest that change in current for *Pkd2*-ecKO arteries is positive, whereas data in Figure 4B indicate a small negative response (about -5 pA). Please clarify this apparent discrepancy or select a more representative trace. Also, explicitly indicate in the Materials and methods the interval over which transient responses were measured.

3\) The sustained, flow-induced reduction in steady state current does not, in and of itself, provide a rationale for the involvement of SK and/or IK channels. The beginnings of a rationale for this supposition, however, might be found in the fact that this reduction is attenuated in mice with EC knockdown of the (minimally?) Ca^2+^-permeable PKD2 channel, which might arguably suggest disruption of a Ca^2+^-dependent process that could involve IK/SK channels. The logical link presented in the original should be modified to make it clear.

10.7554/eLife.56655.sa2

Author response

> Essential revisions:
>
> 1\) The authors should comment on the potential mechanism by which flow increases PKD2 activity.

We agree and have now included potential mechanisms in the Discussion.

> 2\) What do the authors predict the Po-shear stress relationship of PKD2 would be and how would it influence Figure 2E? How would it compare to other flow sensitive channels?

While we understand this request, we feel it is premature to answer this question. Data shown in Figure 2E represent shear stress-mediated activation of endothelial cell PKD2 channels, which stimulates multiple downstream signaling mechanisms, leading to communication between endothelial and smooth muscle cells, resulting in vasodilation, which is the end point that is measured in this figure. It is also unclear whether shear stress directly or indirectly activates PKD2 channels. We respectfully decline this request as we consider it speculative to extrapolate shear stress promoting vasodilation to changes in PKD2 channel P~O~ elicited by shear stress.

> 3\) This lab reported PKD2 expression smooth muscle cells and that these channels contribute to the development of myogenic tone. Together with the new data, that would imply that PKD2 channels are activated by stretch and flow. Are these modes of activation synergistic? Also, how would the function of PKD2 in smooth muscle and endothelial cells would balance to produce a specific vessel response to a change in pressure and flow?

This is an interesting point. Of note, we demonstrated that smooth muscle cell PKD2 channels do not contribute to the myogenic response in mesenteric arteries, which is the preparation we used in this paper under review at *eLife*. Thus, the equilibrium that you suggest due to regulation of PKD2 channels in both cell types would not occur in mesenteric arteries. Pressure stimulates vasoconstriction through the activation of PKD2 channels in smooth muscle cells of hindlimb arteries, but we have not shown that endothelial cell PKD2 channels contribute to flow-mediated vasodilation in this vascular bed (Bulley et al., 2018). Therefore, we consider it premature to speculate on a potential equilibrium mediated by PKD2 in both cell types. We recognize the impact of this important concept and will discuss it in a future study should results consistent with this mechanism be obtained in hindlimb arteries.

> 4\) It would be helpful to include in Figure 2E a third data set showing the PKD2-sensitive component of flow induced changes in diameter.

We agree and have now included this dataset in Figure 2E.

> 5\) The observation that loss of ecPKD2 channels does not alter the response of ECs to ACh. How are these channels modulated by kinases such by mediators of the muscarinic response? Perhaps PKD2 channels are not expressed at distances sufficiently close to AKAPs to be modulated by this signaling pathway.

This is an interesting hypothesis, which we have now discussed in the manuscript. Intracellular signals and kinases that regulate PKD2 channels in endothelial cells are poorly understood. As such, we are unable to conclude whether signaling mechanisms activated by muscarinic receptors are simply incapable of activating PKD2 channels. Our data here and that previously published by others do indicate that PKD2 and TRPV4 channels both activate IK/SK channels and eNOS in endothelial cells. Based on these observations, we agree that compartmentalized signaling is likely to underlie differential regulation of PKD2 channels by flow and muscarinic receptors.

> 6\) The approximate \~33% reduction in PKD2 expression in EC-specific tamoxifen-treated Pkd2^fl/fl^:Cdh5(PAC)-creERT2 mice (Western blotting) seems pretty meager. The description of the methods on this point implies that these data were obtained from whole artery segments, including the smooth muscle layer, which could account for the seemingly modest knockdown. Although immunohistochemistry results suggest a more robust knockdown, these results are qualitative for the most part. In any case, methods used to prepare samples should be clarified and possible explanations for the underwhelming knockdown effect in whole artery segments should be discussed.

As suggested, we have expanded our explanation of these results. Western blotting was performed to quantify proteins in second- through fifth-order branches of mesenteric arteries, as stated in the Materials and methods and now in the Results. The reduction in total PKD2 protein in mesenteric arteries of *Pkd2* ecKO mice is entirely expected. Smooth muscle cells, which also express PKD2 channels, are far more abundant than endothelial cells in these mesenteric arteries. Our data here are consistent with our previous observation that smooth muscle cell-specific PKD2 knockout reduced total mesenteric arterial wall PKD2 protein by \~75 %. Thus, data are consistent with endothelial cells containing 25-30 % of PKD2 protein in the arterial wall, consistent with the Western blotting results shown in Figure 1A and B.

> 7\) Data shown in Figures 4 and 5, taken together with data in Figure 6, suggest that IK/SK and NO should make additive contributions to flow-induced dilation. (There is no obvious mechanism for these two pathways to act in series.) Does application of apamin/Tram-34 together with L-NNA further reduce flow-induced dilation compared with either intervention alone? These data should be included if available.

We agree that this would be interesting to investigate. However, we did not perform this experiment and do not have those data to include in this revised manuscript.

> Presentation issues:
>
> 1\) The authors refer to their model as an EC-specific Pkd2 knockout. It isn\'t. It\'s an EC-specific knockdown (ecKD) model-a fact that might contribute to observed incomplete effects (in addition to the suggested involvement of PKD2-independent mechanisms). Descriptions in the text should be modified to reflect this.

As suggested, we have expanded the text to clarify both our description and the terminology used. We agree that genetic modification may not always completely abolish protein, although there are a wide variety of explanations for such results. The inducible, conditional *Cdh5*(PAC)-creERT2 mouse model we used here to generate our *Pkd2* ecKO mouse has been used by many other groups to knockout proteins in endothelial cells. These papers referred to their mouse models as conditional "knockouts". Rarely did earlier studies provide evidence that the targeting of a specific gene actually reduced the amount of protein in endothelial cells of mice. Even more uncommon has been for investigators to measure the amounts of other proteins to establish the specificity of knockout. Here, we used genomic PCR, Western blotting and immunofluorescence to measure *Pkd2* gene recombination, arterial PKD2 protein and endothelial cell PKD2 protein, respectively. We also measured the expression levels of eight other proteins, which did not change. As we describe in our response to your comment "Revision: \#6", the amount of reduction in PKD2 protein in arteries of the *Pkd2* ecKO mouse is expected. The remaining protein in knockout arteries corresponds to that in smooth muscle cells. The terminology used in the literature to describe the genetic approach we employed here is "knockout". It is up for debate whether "knockout" should only be used for mouse models where it is clearly demonstrated that the protein is completely abolished. "Knockdown" is used to describe mouse models where genetic approaches have been intentionally used to partially reduce the expression of a protein, such as with heterozygotes. As we have no direct evidence to indicate that the mouse line we created is a partial knockdown, we respectfully prefer to use the common terminology of "knockout". Using this term will maintain consistent nomenclature in the literature and reduce confusion for readers regarding the approaches we used to produce our mouse model.

> 2\) It\'s not clear from Figure 4A and B (or the Materials and methods) at what point in the traces transient responses were measured. What is clear from Figure 4A is that the direction of the response in Pkd2-ecKO arteries at a point that would appear to constitute a transient response is opposite that in Pkd2^fl/fl^ arteries. These data suggest that change in current for Pkd2-ecKO arteries is positive, whereas data in Figure 4B indicate a small negative response (about -5 pA). Please clarify this apparent discrepancy or select a more representative trace. Also, explicitly indicate in the Materials and methods the interval over which transient responses were measured.

Thank you for this suggestion. We have now clarified in the Materials and methods and Results that the transient inward current was measured at its peak in each cell. We have replaced the trace for *Pkd2* ecKO in Figure 4A for a more representative one in which the flow-activated transient inward current can be clearly seen. We have now also stated that steady-state inward currents were calculated as the average of at least 45 seconds of continuous data.

> 3\) The sustained, flow-induced reduction in steady state current does not, in and of itself, provide a rationale for the involvement of SK and/or IK channels. The beginnings of a rationale for this supposition, however, might be found in the fact that this reduction is attenuated in mice with EC knockdown of the (minimally?) Ca^2+^-permeable PKD2 channel, which might arguably suggest disruption of a Ca^2+^-dependent process that could involve IK/SK channels. The logical link presented in the original should be modified to make it clear.

As suggested, this logical link has been modified to improve clarity.
